| pubmed-article:11875715 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11875715 | lifeskim:mentions | umls-concept:C1140680 | lld:lifeskim |
| pubmed-article:11875715 | lifeskim:mentions | umls-concept:C0034802 | lld:lifeskim |
| pubmed-article:11875715 | lifeskim:mentions | umls-concept:C1268567 | lld:lifeskim |
| pubmed-article:11875715 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
| pubmed-article:11875715 | lifeskim:mentions | umls-concept:C0919281 | lld:lifeskim |
| pubmed-article:11875715 | lifeskim:mentions | umls-concept:C0879396 | lld:lifeskim |
| pubmed-article:11875715 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:11875715 | pubmed:dateCreated | 2002-3-4 | lld:pubmed |
| pubmed-article:11875715 | pubmed:abstractText | The modulating effects of the orally active epidermal growth factor receptor-specific tyrosine kinase inhibitor ZD 1839 ("Iressa") on cell growth and signalling were evaluated in four ovarian cancer cell lines (PE01, PE04, SKOV-3, OVCAR-5) that express the epidermal growth factor receptor, and in A2780, which is epidermal growth factor receptor-negative. Transforming growth factor-alpha stimulated growth was completely inhibited by concentrations of ZD 1839 > or =0.3 microM in the epidermal growth factor receptor-expressing cell lines, as were transforming growth factor-alpha stimulated phosphorylation of the epidermal growth factor receptor and downstream components of the MAP kinase and PI-3 kinase signalling cascades. Growth inhibition in the absence of added transforming growth factor-alpha was also observed which could be consistent with suppression of action of autocrine epidermal growth factor receptor-activating ligands by ZD 1839. In support of this, transforming growth factor-alpha, EGF and amphiregulin mRNAs were detected by RT-PCR in the epidermal growth factor receptor-expressing cell lines. ZD 1839 inhibited growth of the PE04 ovarian cancer xenograft at 200 mg kg(-1)day(-1). These data lend further support to the view that targeting the epidermal growth factor receptor in ovarian cancer could have therapeutic benefit. | lld:pubmed |
| pubmed-article:11875715 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11875715 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11875715 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11875715 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11875715 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11875715 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11875715 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11875715 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11875715 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11875715 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11875715 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11875715 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11875715 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11875715 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11875715 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11875715 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11875715 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11875715 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11875715 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11875715 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11875715 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11875715 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11875715 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11875715 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11875715 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11875715 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11875715 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:11875715 | pubmed:issn | 0007-0920 | lld:pubmed |
| pubmed-article:11875715 | pubmed:author | pubmed-author:RitchieAA | lld:pubmed |
| pubmed-article:11875715 | pubmed:author | pubmed-author:SmythJ FJF | lld:pubmed |
| pubmed-article:11875715 | pubmed:author | pubmed-author:LangdonS PSP | lld:pubmed |
| pubmed-article:11875715 | pubmed:author | pubmed-author:MacleodK GKG | lld:pubmed |
| pubmed-article:11875715 | pubmed:author | pubmed-author:SewellJ MJM | lld:pubmed |
| pubmed-article:11875715 | pubmed:copyrightInfo | Copyright 2002 The Cancer Research Campaign | lld:pubmed |
| pubmed-article:11875715 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11875715 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:11875715 | pubmed:volume | 86 | lld:pubmed |
| pubmed-article:11875715 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11875715 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11875715 | pubmed:pagination | 456-62 | lld:pubmed |
| pubmed-article:11875715 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:11875715 | pubmed:meshHeading | pubmed-meshheading:11875715... | lld:pubmed |
| pubmed-article:11875715 | pubmed:meshHeading | pubmed-meshheading:11875715... | lld:pubmed |
| pubmed-article:11875715 | pubmed:meshHeading | pubmed-meshheading:11875715... | lld:pubmed |
| pubmed-article:11875715 | pubmed:meshHeading | pubmed-meshheading:11875715... | lld:pubmed |
| pubmed-article:11875715 | pubmed:meshHeading | pubmed-meshheading:11875715... | lld:pubmed |
| pubmed-article:11875715 | pubmed:meshHeading | pubmed-meshheading:11875715... | lld:pubmed |
| pubmed-article:11875715 | pubmed:meshHeading | pubmed-meshheading:11875715... | lld:pubmed |
| pubmed-article:11875715 | pubmed:meshHeading | pubmed-meshheading:11875715... | lld:pubmed |
| pubmed-article:11875715 | pubmed:meshHeading | pubmed-meshheading:11875715... | lld:pubmed |
| pubmed-article:11875715 | pubmed:meshHeading | pubmed-meshheading:11875715... | lld:pubmed |
| pubmed-article:11875715 | pubmed:meshHeading | pubmed-meshheading:11875715... | lld:pubmed |
| pubmed-article:11875715 | pubmed:meshHeading | pubmed-meshheading:11875715... | lld:pubmed |
| pubmed-article:11875715 | pubmed:meshHeading | pubmed-meshheading:11875715... | lld:pubmed |
| pubmed-article:11875715 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:11875715 | pubmed:articleTitle | Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ("Iressa"). | lld:pubmed |
| pubmed-article:11875715 | pubmed:affiliation | Imperial Cancer Research Fund Medical Oncology Unit, Western General Hospital, Edinburgh EH4 2XU, Scotland, UK. | lld:pubmed |
| pubmed-article:11875715 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11875715 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11875715 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11875715 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11875715 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11875715 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11875715 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11875715 | lld:pubmed |
